Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanofi PER.C6 cell-based influenza vaccine
- Development stage
- Discontinued
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Sanofi PER.C6 cell-based influenza vaccine is an experimental, trivalent, split-virion inactivated vaccine produced using the proprietary PER.C6 human embryonic retinal cell line. Developed through a 2003 partnership between Sanofi Pasteur and Crucell N.V., this vaccine was designed to provide an alternative to traditional egg-based manufacturing, potentially offering a more scalable and reliable production method for both seasonal and pandemic influenza. The vaccine contains hemagglutinin (HA) antigens from two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage. Although it demonstrated a manageable safety profile in Phase 1 and Phase 2 clinical trials, it showed lower immunogenicity (antibody titers) compared to Sanofi's egg-based Fluzone, leading to the cessation of its development in favor of other technologies like recombinant protein vaccines.
- Other names
- cell-based influenza vaccine (PER.C6)Sanofi-Crucell influenza vaccineInfluenza virus vaccine - cell based (2007-2008 Formulation)
02
Targets
H5 HA (Influenza A hemagglutinin H5)HA (Hemagglutinin)
Beyond the preview
Go deeper on Sanofi PER.C6 cell-based influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanofi PER.C6 cell-based influenza vaccine.